Cargando…

Use of and Retention on Video, Telephone, and In-Person Buprenorphine Treatment for Opioid Use Disorder During the COVID-19 Pandemic

IMPORTANCE: The coronavirus disease 2019 (COVID-19) pandemic prompted policy changes to allow increased telehealth delivery of buprenorphine, a potentially lifesaving medication for opioid use disorder (OUD). It is unclear how characteristics of patients who access different treatment modalities (in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frost, Madeline C., Zhang, Lan, Kim, H. Myra, Lin, Lewei (Allison)
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9557869/ https://www.ncbi.nlm.nih.gov/pubmed/36223118 http://dx.doi.org/10.1001/jamanetworkopen.2022.36298

Ejemplares similares

Removal of Medicaid Prior Authorization Requirements and Buprenorphine Treatment for Opioid Use Disorder
por: Christine, Paul J., et al.
Publicado: (2023)

Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees
por: Hammerslag, Lindsey R., et al.
Publicado: (2023)

Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder
por: Flam-Ross, Juliet M., et al.
Publicado: (2023)

Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder During the COVID-19 Pandemic
por: Currie, Janet M., et al.
Publicado: (2021)

Mobile Telemedicine for Buprenorphine Treatment in Rural Populations With Opioid Use Disorder
por: Weintraub, Eric, et al.
Publicado: (2021)

Personalized Care in Opioid Use Disorder maintained on Buprenorphine
por: Elarabi, H., et al.
Publicado: (2022)

Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use
por: Xu, Kevin Y., et al.
Publicado: (2022)

High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder
por: Herring, Andrew A., et al.
Publicado: (2021)

Implementation Facilitation to Promote Emergency Department–Initiated Buprenorphine for Opioid Use Disorder
por: D’Onofrio, Gail, et al.
Publicado: (2023)

Characteristics of US Counties With High Opioid Overdose Mortality and Low Capacity to Deliver Medications for Opioid Use Disorder
por: Haffajee, Rebecca L., et al.
Publicado: (2019)

Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees
por: Wen, Hefei, et al.
Publicado: (2018)

Analysis of Stimulant Prescriptions and Drug-Related Poisoning Risk Among Persons Receiving Buprenorphine Treatment for Opioid Use Disorder
por: Mintz, Carrie M., et al.
Publicado: (2022)

Buprenorphine Dose and Time to Discontinuation Among Patients With Opioid Use Disorder in the Era of Fentanyl
por: Chambers, Laura C., et al.
Publicado: (2023)

Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail
por: Lee, Joshua D., et al.
Publicado: (2021)

Lower buprenorphine elimination rate constant is associated with lower opioid use
por: Elarabi, Hesham Farouk, et al.
Publicado: (2022)

Association of a Multimodal Educational Intervention for Primary Care Physicians With Prescriptions of Buprenorphine for Opioid Use Disorders
por: Clark, Brinton, et al.
Publicado: (2019)

A buprenorphine-validated rat model of opioid use disorder optimized to study sex differences in vulnerability to relapse
por: Bakhti-Suroosh, Anousheh, et al.
Publicado: (2021)

Association of Project ECHO Training With Buprenorphine Prescribing by Primary Care Clinicians in Minnesota for Treating Opioid Use Disorder
por: Solmeyer, Anna R., et al.
Publicado: (2022)

Buprenorphine Use Trends Following Removal of Prior Authorization Policies for the Treatment of Opioid Use Disorder in 2 State Medicaid Programs
por: Keshwani, Shailina, et al.
Publicado: (2022)

The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder
por: De Aquino, Joao P., et al.
Publicado: (2021)

Buprenorphine treatment retention and comorbidities among patients with opioid use disorder in a primary care setting
por: Sweeney, Mary M., et al.
Publicado: (2022)

Buprenorphine‐naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder
por: Kanervo, Minna M., et al.
Publicado: (2022)

Adoption of Emergency Department–Initiated Buprenorphine for Patients With Opioid Use Disorder: Secondary Analysis of a Cluster Randomized Trial
por: Gao, Evangeline, et al.
Publicado: (2023)

Perspectives of Clinicians and Staff at Community-Based Opioid Use Disorder Treatment Settings on Linkages With Emergency Department–Initiated Buprenorphine Programs
por: Sue, Kimberly L., et al.
Publicado: (2023)

Association Between Hospital Adoption of an Emergency Department Treatment Pathway for Opioid Use Disorder and Patient Initiation of Buprenorphine After Discharge
por: Solomon, Keisha T., et al.
Publicado: (2023)

Characteristics and Prescribing Patterns of Clinicians Waivered to Prescribe Buprenorphine for Opioid Use Disorder Before and After Release of New Practice Guidelines
por: Jones, Christopher M., et al.
Publicado: (2023)

Prescribing Characteristics Associated With Opioid Overdose Following Buprenorphine Taper
por: Bozinoff, Nikki, et al.
Publicado: (2022)

Inpatient Buprenorphine Induction for Opioid Use Disorder in Pregnancy
por: Tavakoli, Amin, et al.
Publicado: (2023)

Trends in Out-of-Pocket Costs for and Characteristics of Pharmacy-Dispensed Buprenorphine Medications for Opioid Use Disorder Treatment by Type of Payer, 2015 to 2020
por: Strahan, Andrea E., et al.
Publicado: (2023)

Cost-effectiveness of Increasing Buprenorphine Treatment Initiation, Duration, and Capacity Among Individuals Who Use Opioids
por: Claypool, Anneke L., et al.
Publicado: (2023)

Patients Maintained on Buprenorphine for Opioid Use Disorder Should Continue Buprenorphine Through the Perioperative Period
por: Lembke, Anna, et al.
Publicado: (2019)

Opioid replacement therapy with methadone or buprenorphine effects on male mice reproduction
por: Moinaddini, Fatemeh, et al.
Publicado: (2022)

The Coronavirus Disease Pandemic Continues to Challenge Patients in Need of Buprenorphine for Opioid Use Disorder
por: Routsolias, Joanne C., et al.
Publicado: (2021)

Prescription amphetamines in people with opioid use disorder and co-occurring psychostimulant use disorder initiating buprenorphine: an analysis of treatment retention and overdose risk
por: Tardelli, Vitor, et al.
Publicado: (2023)

A review of the pharmacogenomics of buprenorphine for the treatment of opioid use disorder
por: Seguí, Hemanuel Arroyo, et al.
Publicado: (2020)

Hospitalist perspectives on buprenorphine treatment for inpatients with opioid use disorder
por: Reed, Megan K, et al.
Publicado: (2022)

Pharmacy Availability of Buprenorphine for Opioid Use Disorder Treatment in the US
por: Weiner, Scott G., et al.
Publicado: (2023)

Association between Participation in Counseling and Retention in a Buprenorphine-Assisted Treatment Program for People Experiencing Homelessness with Opioid Use Disorder
por: Berry, Amanda R. W., et al.
Publicado: (2021)

Quality of Opioid Use Disorder Treatment for Persons With and Without Disabling Conditions
por: Thomas, Cindy Parks, et al.
Publicado: (2023)

Patient Satisfaction with In-Person, Video, and Telephone Allergy/Immunology Evaluations During the COVID-19 Pandemic
por: Mustafa, S. Shahzad, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mp5eo3khumj08kbafqjr8cj07k